Exo entered the handheld ultrasound device market with the Iris, a chip-scale system that uses piezoelectric micromachined ultrasound transducer (PMUT) technology rather than the traditional piezoelectric crystal approach found in most clinical systems. The distinction matters for practices evaluating this platform because PMUT chips produce a single-probe form factor that covers a wider clinical range than a conventional handheld, which typically requires swapping transducers between applications. Financing an Exo Iris fleet for a practice or health system means understanding what that platform delivers clinically and whether the economics justify the per-unit price point.
We finance Exo systems starting at $50,000. A multi-unit Exo Iris deployment for a clinical team or department typically lands well above that threshold, and application-only approval handles requests up to approximately $400,000 with streamlined documentation. Three months of bank statements and an application are the core requirements for most established practices. Funding takes one to two weeks from approval. B and C credit profiles are considered; the cash in the accounts and the revenue the practice demonstrates often matter more than the score number.
The practices that pull the trigger on Exo financing tend to be departments that want to put imaging in more hands, not just in more rooms. An emergency group equipping every physician with a dedicated device, or a hospitalist service adding bedside scanning as a standard workflow, represents a different deployment model than buying one cart for a department. We structure the financing to fit that model, whether that is one device on a single application or a fleet purchase spread across a group practice.